ABBV

AbbVie, Inc.

Healthcare


Presented:08/13/2020
Price:$94.68
Cap:$167.09B
Current Price:$191.86
Cap:$338.89B

Presented

Date08/13/2020
Price$94.68
Market Cap$167.09B
Ent Value$243.12B
P/E Ratio20.14x
Book Value$8.34
Div Yield4.87%
Shares O/S1,764.83M
Ave Daily Vol8,110,899
Short Int0.75%

Current

Price$191.86
Market Cap$338.89B
AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson's disease; metabolic diseases, comprising thyroid disease and complications associated with cystic fibrosis; pain associated with endometriosis; and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.

Publicly traded companies mentioned herein: AbbVie Inc (ABBV), Bristol-Myers Squibb Co (BMY), Pfizer Inc (PFE)

Highlights

On June 25, 2019, AbbVie (ABBV) announced the acquisition of Allergan. The stock is up ~$20/share since then, but the presenter thinks passive/long only sponsorship has yet to come. And, such sponsorship, paired with better than expected results and optimism about 2021, could help sustain a move to above $100/share. With bond yields at all-time lows and a ~5% yield, ABBV is even harder to ignore (in his opinion, “it could be the right asset at the right time”). He is long the stock in the mid-$90s and sees the potential for the stock to rise to $120 over the next 6-12 months as it becomes [more] apparent that Skyrizi and Rinvoq will help offset generic risk to the Humira franchise over coming years, and multiple chip shots (outlined below) create optionality for shareholders.

  • Signing up and creating account with us unlocks this content for you. Contact us today for full access to DeMatteo Research and more.

  • Signing up and creating account with us unlocks this content for you. Contact us today for full access to DeMatteo Research and more.

Request access to DeMatteo Research for full access

Request Access

Already have an account?

Idea Discussion

Commentor 1 - 2 weeks ago

Signing up and creating account with us, unlocks this content for you. Contact us today for full access to DeMatteo Research and more.

Commentor 1 - 2 weeks ago

Signing up and creating account with us, unlocks this content for you. Contact us today for full access to DeMatteo Research and more.

Idea Discussions display submitted commentary from our investor community.

To read and participate in the discussion with the presenter and investor base, request access to DeMatteo

Request Access

Already have an account?

An error occurred loading this content. Try again later or contact us.